Patient no | Family | Sex | Current age | Age at onset | Previous diagnosis | Previous treatment | Current treatment |
1 | Family 1 | F | 25 years | 10 months | JIA, Behçet disease | CS, MTX, CYS | MTX, thalidomide |
2 | Family 1 | F | 23 years | 15 months | JIA, Behçet disease | CS, MTX, CYS, AZA, thalidomide, IVIG, ETN | IFX |
3 | Family 1 | F | 51 years | Early 20s | Rheumatoid arthritis (RF−), Behçet disease | None | Colchicine |
4 | Family 2 | F | 25 years | 10 years | JIA, undifferentiated connective tissue disease/cutaneous vasculitis, SLE with CNS vasculitis | CS, MMF, ETN, thalidomide, RTX, IFX, MTX, ADA, cyclo, IVIG, autologous haematopoietic stem cell transplant | Anakinra, AZA, CS |
5 | Family 2 | F | 29 years | Around 8 years | Behçet disease, lupus nephritis | CS, colchicine, ETN, hydroxychloroquine | Anakinra |
6 | Family 2 | F | 51 years | Around 6 years | Rheumatic fever, arthritis | None | Anakinra |
7 | Family 2 | F | 56 years | Around 6 years | None | Anakinra | |
8 | Family 3 | M | 9 years | 9 months | Behçet disease | CS, colchicine, AZA | Colchicine |
9 | Family 3 | M | 46 years | ? | Behçet disease | On treatment (not specified) | |
10 | Family 4 | F | 15 years | 8 weeks | Suspicion of PFAPA | CS, colchicine, ETN, anakinra, ADA, MTX | Tofacitinib |
11 | Family 5 | F | 17 years | Around 4 years | Suspicion of Behçet disease | CYS, dapsone, CS, AZA, IVIG for Ig deficiency | IFX |
12 | Family 5 | F | 47 years | Infancy | Suspicion of Behçet disease | CS, colchicine, AZA, IFX, IVIG for Ig deficiency | None |
13 | Family 6 | F | 38 years | 29 years | Behçet disease | None | Colchicine |
14 | Family 6 | F | 19 years | 15 years | Suspicion of Behçet disease | None | Colchicine |
15 | Family 6 | F | 15 years | 13 years | Suspicion of Behçet disease | None | Colchicine |
16 | Family 7 | M | (8 years)† | 1 week | Crohn’s disease, Behçet disease | CS, mesalamine, dapsone, MTX, AZA, colchicine, IFX, ADA, certolizumab, anakinra, canakinumab, tacrolimus, IVIG, tocilizumab | NA |
ADA, adalimumab; AZA, azathioprine; CNS, central nervous system; CS, systemic corticosteroids; cyclo, cyclophosphamide; CYS, ciclosporin; ETN, etanercept; F, female; IFX, infliximab; IVIG, intravenous immunoglobulin; JIA, juvenile idiopathic arthritis; M, male; MTX, methotrexate; NA, not applicable; PFAPA, periodic fever, aphthous stomatitis, pharyngitis, adenitis; RF, rheumatoid factor; SLE, systemic lupus erythematosus.